KalshiVerifica disponibilitàKYC richiesto2% di commissioneDati di risoluzione verificatiDiscretamente calibratoProbabilità implicita attuale
Sì 98%
Qualità del mercato
45 / 100
Bassa qualitàVolume 24h
644,9 €
Liquidità
1,9K €
Bassa liquiditàBid / Ask
77.0% / 99.0%
Spread
22.0 pt
Spread ampioDati di mercato
Aggiornato 6 minuti fa
17 giu 26, 21:00 UTC1 gen 27, 04:59 UTC
Trend
Mercati Correlati
Domande correlate per il contesto, non un confronto tra contratti equivalenti.
FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiFDA decision: Venglustat by Sanofi (in 2026)
KalshiFDA decision: Ivonescimab by Summit Therapeutics (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegole
If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Si regola tramite:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Bepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep.
- It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions.
- This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.
Mercati aperti
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Volume totale
- 15,6 Mln €
- Volume 24h
- 18,3K €
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Volume totale
- 1,6 Mln €
- Volume 24h
- 5,2K €
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 altri esiti
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Volume totale
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Volume totale
- 916K €
- Volume 24h
- 1,5K €
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 altri esiti
- Volume totale
- 863,6K €
- Volume 24h
- 1K €
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
- When will Compass Pathways submit a NDA for COMP360 psilocybin?
Domande frequenti
- Quali sono le probabilità attuali per FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi quota Yes al 98% al 8 settembre 2026.
- Quando si risolve FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026) dovrebbe risolversi il 1 gennaio 2027.
- Come viene liquidato FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)?
- Kalshi liquida questo mercato come segue: If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.